Title:ZNF695, A Potential Prognostic Biomarker, Correlates with Im mune
Infiltrates in Cervical Squamous Cell Carcinoma and Endoce rvical
Adenocarcinoma: Bioinformatic Analysis and Experimental Verification
Volume: 24
Issue: 5
Author(s): Xiaojuan Ding, Ailing Wan, Xin Qi, Ke'er Jiang, Zhao Liu and Buze Chen*
Affiliation:
- The First Clinical Medical College, Xuzhou Medical University, Xuzhou,
221000, Jiangsu, China
- Huaihai Institute of Traditional Chinese Medicine, Xuzhou Medical University, Xuzhou,
221000, Jiangsu, China
- Department of Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou,
221000, Jiangsu, China
Keywords:
Cervical squamous cell carcinoma, endocervical adenocarcinoma, ZNF695, prognosis, immune infiltration, drug sensitivity, therapy target.
Abstract:
Background: The role of Zinc Finger Protein 695 (ZNF695) is unclear in cervical squamous
cell carcinoma and endocervical adenocarcinoma (CESC).
Objective: The objective of this study was to conduct a comprehensive analysis and experimental
validation of ZNF695 in CESC.
Methods: The study investigated the expression of ZNF695 in both pan-cancer and CESC, utilizing
data from The Cancer Genome Atlas (TCGA) database to assess its diagnostic value. The present
study investigated the association between ZNF695 expression levels and clinical characteristics,
as well as prognosis, in patients with CESC. The study explored potential regulatory networks
involving ZNF695, including its association with immune infiltration, immune score, stemness
index based on mRNA expression (mRNAsi), and drug sensitivity in CESC. We explored the
expression of ZNF695 in CESC single cells. ZNF695 expression was validated using GSE29570.
Results: ZNF695 was found to be aberrantly expressed in pan-cancer and CESC. There was a significant
correlation observed between an elevated level of ZNF695 expression in patients with
CESC and histological grade (p = 0.017). Furthermore, a strong association was found between
high ZNF695 expression in CESC patients and poorer overall survival (OS) (HR: 1.87; 95% CI:
1.17-3.00; p = 0.009), Progression-free Survival (PFS) (HR: 1.86; 95% CI: 1.16-2.98; p = 0.010),
and Disease-specific Survival (DSS) (HR: 1.98; 95% CI: 1.15-3.42; p = 0.014). The expression of
ZNF695 in CESC patients (p = 0.006) was identified as an independent prognostic determinant.
ZNF695 was associated with steroid hormone biosynthesis, oxidative phosphorylation, and so on.
ZNF695 expression correlated with immune infiltration, immune score, and mRNAsi in CESC.
ZNF695 expression significantly and negatively correlated with AICA ribonucleotide, BIX02189,
QL-XI-92, STF-62247, and SNX-2112 in CESC. ZNF695 gene was upregulated in CESC tissues
and cell lines. ZNF695 was significantly upregulated in the CESC cell lines.
Conclusion: ZNF695 may be a potential prognostic biomarker and immunotherapeutic target for
CESC patients.